Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.
Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 3, 11, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.
Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Gonorrhea - Overview
Gonorrhea - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Gonorrhea - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Gonorrhea - Companies Involved in Therapeutics Development
Biolytics Pharma
Boulos and Cooper Pharmaceuticals Pty Ltd
Debiopharm International SA
Entasis Therapeutics Holdings Inc
GlaxoSmithKline Plc
Hsiri Therapeutics LLC
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Nabriva Therapeutics Plc
Pharmiva AB
Redx Pharma Plc
TherapyX Inc
Yaso Therapeutics Inc
Gonorrhea - Drug Profiles
BCP-1 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Gonorrhea - Drug Profile
Product Description
Mechanism Of Action
Debio-1453 - Drug Profile
Product Description
Mechanism Of Action
History of Events
edodekin alfa SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
Fusion Protein for Gonorrhea - Drug Profile
Product Description
Mechanism Of Action
gepotidacin mesylate - Drug Profile
Product Description
Mechanism Of Action
History of Events
GneXa10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
gonorrhea vaccine - Drug Profile
Product Description
Mechanism Of Action
gonorrhea vaccine - Drug Profile
Product Description
Mechanism Of Action
gonorrhea vaccine - Drug Profile
Product Description
Mechanism Of Action
KKL-35 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lefamulin acetate - Drug Profile
Product Description
Mechanism Of Action
History of Events
MBX-4132 - Drug Profile
Product Description
Mechanism Of Action
History of Events
methyldopa - Drug Profile
Product Description
Mechanism Of Action
NGoXIM - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-002 - Drug Profile
Product Description
Mechanism Of Action
PEG-2S - Drug Profile
Product Description
Mechanism Of Action
PPCM - Drug Profile
Product Description
Mechanism Of Action
History of Events
RXP-2382 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit DNA Gyrase and Topoisomerase IV for Gonorrhea - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit PBP2 for Gonorrhea - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Tubulin for Gonorrhea and Oncology - Drug Profile
Product Description
Mechanism Of Action
solithromycin - Drug Profile
Product Description
Mechanism Of Action
History of Events
zoliflodacin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gonorrhea - Dormant Projects
Gonorrhea - Discontinued Products
Gonorrhea - Product Development Milestones
Featured News & Press Releases
Mar 19, 2021: PENN STATE: New antibiotic clears multi-drug resistant gonorrhea in mice in single dose
Feb 12, 2021: GARDP welcomes additional funding from UK to develop new treatment for gonorrhoea
Nov 08, 2019: Debiopharm progresses in their stand against drug-resistant N. Gonorrhoeae with extended CARB-X funding of their Debio 1453 Antibiotic Program
Oct 28, 2019: £184 million loan funding for urgent hospital upgrades
Sep 30, 2019: GARDP and Entasis Therapeutics initiate global phase 3 trial of Zoliflodacin, a first-in-class oral antibiotic for the treatment of Gonorrhea
Jun 27, 2019: Entasis Therapeutics presents on zoliflodacin at ASM Microbe 2019
Jun 10, 2019: Entasis Therapeutics announces presentation on zoliflodacin at ASM Microbe 2019
May 14, 2019: Institute for Glycomics shares in multi-million dollar grant for ground-breaking gonorrhoea research
Mar 13, 2019: Yaso Therapeutics awarded $2 million SBIR grant from the National Institutes of Health to complete preclinical studies of a new female contraceptive that prevents disease transmission
Nov 08, 2018: Data from NIH-funded trial offers hope for gonorrhoea treatment
Nov 07, 2018: Entasis Therapeutics announces zoliflodacin phase 2 results published in the new England journal of medicine
Jul 25, 2017: Debiopharm International Awarded $2.6 Million Grant from CARB-X to Support Development of Debio 1453 to Fight Drug Resistant Gonorrhea
Jun 02, 2017: Eight Presentations at ASM Microbe Include Late Breaker From Cempra’s Phase 3 Fusidic Acid Study and Solithromycin Data on Gonorrhea and Otitis Media
Oct 28, 2016: Entasis Therapeutics to Present Data on ETX0914 at IDWeek 2016
Sep 21, 2016: Entasis Announces Positive Phase 2 Data of ETX0914 for the Treatment of Gonorrhea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Gonorrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Gonorrhea - Pipeline by Biolytics Pharma, 2022
Gonorrhea - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2022
Gonorrhea - Pipeline by Debiopharm International SA, 2022
Gonorrhea - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Gonorrhea - Pipeline by GlaxoSmithKline Plc, 2022
Gonorrhea - Pipeline by Hsiri Therapeutics LLC, 2022
Gonorrhea - Pipeline by Melinta Therapeutics Inc, 2022
Gonorrhea - Pipeline by Merck & Co Inc, 2022
Gonorrhea - Pipeline by Microbiotix Inc, 2022
Gonorrhea - Pipeline by Nabriva Therapeutics Plc, 2022
Gonorrhea - Pipeline by Pharmiva AB, 2022
Gonorrhea - Pipeline by Redx Pharma Plc, 2022
Gonorrhea - Pipeline by TherapyX Inc, 2022
Gonorrhea - Pipeline by Yaso Therapeutics Inc, 2022
Gonorrhea - Dormant Projects, 2022
Gonorrhea - Discontinued Products, 2022
List of Figures
Number of Products under Development for Gonorrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
